Immix Biopharma, Inc.
IMMXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the. The $640.7M market capitalization puts IMMX squarely in small-cap range for its industry. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Market Cap
$640.7M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-13.90
EPS (TTM)
$-0.92
EPS (Fwd)
$-0.65
ROE
-74.5%
ROA
-39.0%
Cash
$90.6M
Total Debt
$1.0M
Free CF
-$20.0M
52W Change
246.2%
Annual Financials
Cash vs Debt
With $90.6M in cash and $1.0M in debt, IMMX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$20.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -74.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, IMMX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Immix Biopharma, Inc.'s trajectory.